Biotechnology: Vaccine Development : Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, First Session, March 13, 1985, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 1985 - Biotechnology - 270 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
accelerated activities additional amount analysis animals antibodies antigens approach attenuated basic benefits budget candidate cause cells clinical trials Coccidioides immitis committee CONGRESS THE LIBRARY cost countries deaths determine DINGELL Early effective efficacy estimates expected funding genes genetic genital herpes going grants hepatitis herpes human identified immunization important improved infants infections Infectious Diseases influenza Institute involved JORDAN laboratory less LIBRARY OF CONGRESS live major Mason material measles Medicine million NIAID organisms patients percent pertussis pertussis vaccine possible potential prepared prevent priority problem produce progress proposed protective protein public health question rank recent reduce request Respiratory response result rotavirus selection SELL SIKORSKI specific strain studies subunit successful tested treatment trials understanding United vaccine development Value virus viruses WARREN
Page 36 - The author's own research is supported by the National Health and Medical Research Council, Canberra, Australia and by Grant No. AI-03958 from the National Institute for Allergy and Infectious Diseases, US Public Health Service.
Page 28 - As many as 101' particles (10 million million) can be present per millilitre of blood plasma. It is possible to bleed donors in such a manner as to remove the fluid (plasma) component of blood, but to return the white and red blood cells. Further, the HBsAg can then be purified from donated plasma and sterilized.
Page 37 - Bittle, JL, Houghten, RA, Alexander, H., Shinnick, TM, Sutcliffe, JG, Lerner, RA, Rowlands, DJ, and Brown, F.
Page 172 - Microbiology and Infectious Diseases Program National Institute of Allergy and Infectious Diseases National Institutes of Health Westwood Building - Room 750 Bethesda, Maryland 20205 Bruce A.
Page 24 - Overall, there is evidence that human vaccines are less profitable investments for the pharmaceutical industry than are drugs, and this would be even more the case for those vaccines required particularly for developing countries, with their lesser ability to pay. The second constraint relates to the changing perceptions of regulatory agencies. Pasteur's rabies vaccine or even Jenner's smallpox vaccine would have great difficulties in today's regulatory climate, and indeed even the first tentative...
Page 20 - Living or killed microorganisms frequently present antigens to the immune system. as a bristling array of hundreds or thousands of molecules packed closely together, on the surface of the microbe. This, for technical reasons which need not detain us, increases the intensity of the immune response (6) . Furthermore, the microparticulate nature of microorganisms makes them palatable to the body's scavenger cells, and scavenger cell-associated antigen is a much more powerful trigger to the immune system...
Page 200 - Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration, "Summary of Clinical Trials of Influenza Vaccines," Journal of Infectious Diseases 134 (Jul.
Page 135 - Health (NIK), with liaison from the Department of Defense, has been an effective forum for coordinating issues relating to vaccines. Some recent accomplishments include the preparation of progress reports on pertussis vaccines and proposals for mechanisms to deal...
Page 43 - Hardly anyone doubts the validity of the claim that "never in the history of human progress has a better and cheaper method of preventing illness been developed than immunization at its best.
Page 17 - One little corner of a protein, say a peptide. 10 amino acids in length, may suffice to give protection, though, as we shall see, some tricks have to be used to make this work, whole protein molecules can be made synthetically from amino acids, but the bigger the protein, the greater the risk of introducing an error into the sequence ar. : more cumbersome the synthesis. These difficulties mean that, in practice, synthetic proteins are 50 or less amino acids long. So much emphasis is c into defining...